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Abstract
Tumors are thought to be sustained by a reservoir of self-renewing cells, termed tumor initiating
cells or cancer stem cells. Osteosarcomas are high-grade sarcomas derived from osteoblast
progenitor cells and are the most common pediatric bone malignancy. In this report we show that
the stem cell transcription factor Sox2 is highly expressed in human and murine osteosarcoma cell
lines as well as in tumor samples. Osteosarcoma cells have increased ability to grow in suspension
as osteospheres, that are greatly enriched in expression of Sox2 and the stem cell marker, Sca-1.
Depletion of Sox2 by shRNAs in independent murine osteosarcoma-derived cells drastically
reduces their transformed properties in vitro and their ability to form tumors. Sox2-depleted
osteosarcoma cells can no longer form osteospheres, and differentiate into mature osteoblasts.
Concomitantly, they exhibit decreased Sca-1 expression and upregulation of the Wnt signaling
pathway. Thus, despite other mutations, these tumor cells maintain a proliferative requirement for
Sox2. Our data indicate that Sox2 is required for osteosarcoma cell self-renewal, and that Sox2
antagonizes the pro-differentiation Wnt pathway, that can in turn reduce Sox2 expression. These
studies define Sox2 as a survival factor and a novel biomarker of self-renewal in osteosarcomas,
and support a tumor suppressive role for the Wnt pathway in tumors of mesenchymal origin. Our
findings could provide the basis for novel therapeutic strategies based on inhibiting Sox2 or
enhancing Wnt signaling for the treatment of osteosarcomas.
Keywords
Sox2; osteosarcoma; Wnt signaling; cancer stem cell; tumor initiating cell; mesenchymal tumors;
differentiation; sarcosphere
Introduction
The hypothesis that tumor maintenance depends on a subpopulation of cells that self-renew,
and that are often referred to as tumor initiating or cancer stem cells (CSCs), has recently
received considerable attention (Clarke et al 2006, Kim and Dirks 2008, Shackleton et al
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t2009). Self-renewing, stem cell-like, cells were first identified in acute myeloid leukemia,
and have more lately been observed in diverse solid tumors (Buzzeo et al 2007, Clarke et al
2006, Kim and Dirks 2008). CSCs have the capacity of symmetric as well as of asymmetric
division, and appear more drug-resistant than bulk tumor (Fujii et al 2009, Shackleton et al
2009).
Osteosarcomas, the most common primary, non-hematologic malignant tumors in childhood
and adolescence, comprise almost 60% of the common histologic subtypes of bone sarcomas
(Cormier and Pollock 2004, Heare et al 2009). Since the advent of chemotherapy, the long-
term cure rate for non-metastatic osteosarcomas following amputation has risen from 25% to
60-70%. However, the survival rate for metastatic osteosarcoma has not improved over the
last 30 years, and ∼ 40% of osteosarcoma patients succumb to the disease (Heare et al 2009,
Levings et al 2009, Tabone et al 1994). A better understanding of how these tumors
originate and progress is needed for the development of targeted therapies for both primary
and metastatic osteosarcomas.
Molecular genetic analysis of sporadic and hereditary osteosarcomas in humans
demonstrated that inactivation of the tumor suppressors Rb and p53 plays a role in their
development. Osteosarcomas are the second most frequent tumor in patients with hereditary
retinoblastoma, and individuals with germ line mutation in the RB-1 gene have a 500- fold
increased risk of osteosarcoma as compared to the general population (Helman and Meltzer
2003, Wadayama et al 1994). Osteosarcomas contain highly proliferative malignant cells
that are largely arrested in their differentiation (Tang et al 2008, Thomas et al 2004).
Although osteosarcomas derive from the osteoblastic lineage, the nature of the cell of origin
is unclear. However, murine osteosarcomas originate at high frequency in mice following
conditional knock-out (KO) of the Rb-1 and p53 genes in the osteoblastic lineage (Berman
et al 2008, Walkley et al 2008). These osteosarcoma cells express several genes
characteristic of stem cells, such as the hematopoetic and mesenchymal stem cell antigen,
Sca-1 (Morikawa et al 2009, Walkley et al 2008) The presence of osteosarcoma stem-like
cells has been reported in patient tumors as well as in established human osteosarcoma cell
lines (Gibbs et al 2005, Levings et al 2009). While these studies have alluded to the
existence of osteosarcoma stem cells, they have not identified a direct mechanism by which
these cells originate and how these stem cells can be targeted for tumor abrogation.
Activation of several signaling pathways such as fibroblast growth factor (FGF) and Wnt
signaling have been implicated in the etiology of osteosarcomas and could contribute to the
maintenance of an osteosarcoma stem cells niche.
We and others have previously shown that FGF stimulates proliferation and blocks
differentiation of immature osteoblasts (Mansukhani et al 2000, Mansukhani et al 2005,
Marie 2003). Furthermore FGF signaling antagonizes the Wnt pathway, that promotes
differentiation (Ambrosetti et al 2008). In osteoblasts, FGF induces the transcription factor,
Sox2, and similar to FGF treatment, constitutive Sox2 expression can by itself prevent
differentiation (Mansukhani et al 2005). Sox2 is a transcription factor of the HMG domain
family that plays a critical role in embryonic development and in maintaining pluripotency
and self-renewal in embryonic stem (ES) cells (Avilion et al 2003, Lefebvre et al 2007,
Niwa 2007, Yuan et al 1995) and several cell lineages such as neural (Pevny and Nicolis
2010) and tracheal cells (Que et al 2009). We have recently demonstrated that Sox2 is
necessary for the self-renewal of the osteoblast lineage. Conditional, bone-specific Sox2
knock-out leads to an osteopenic phenotype in mice, and inactivation of Sox2 in cell culture
abolishes the proliferative capacity of normal osteoblasts (Basu-Roy et al 2010). In addition,
“osteospheres”, osteoblasts growing as spherical clusters in suspension and believed to
represent a self-renewing, multipotent, stem cell-like population (Gutierrez et al 2008),
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texhibit high Sox2 expression, consistent with Sox2 serving as a marker of a subpopulation
of self-renewing osteoprogenitors (Basu-Roy et al 2010).
In the present study, we have investigated the role of Sox2 in osteosarcoma. Our data show
that Sox2 is highly expressed in human and murine osteosarcoma cells lines as compared to
normal osteoblasts. Knock-down of Sox2 by shRNA in murine osteosarcoma cell lines
decreases colony formation. Cells stably expressing Sox2 shRNA show reduced Sox2
expression, invasion and migration, as well as tumor formation in immunocompromised
mice. Furthermore, downregulation of Sox2 expression results in increased activity of the
Wnt signaling pathway. Following Sox2 depletion, osteosarcoma cells display accelerated
differentiation into mature bone-forming cells and decreased Sca-1 expression. Based on
these findings, we propose that Sox2 marks a population of tumor initiating, cancer stem
cells and that its function is required for their self-renewal and tumorigenicity.
Results
Sox2 is highly expressed in human and mouse osteosarcoma cell lines
Previously we reported that Sox2 is expressed in U-2OS osteosarcoma cells (Mansukhani et
al 2005). We have now examined Sox2 expression in seven independent human
osteosarcoma cell lines and have found that Sox2 mRNA and protein are over-expressed in
all cell lines as compared to primary human osteoblasts (Figure 1A). We also tested Sox2
expression by immunohistochemistry in a panel of human osteosarcomas and found that all
of them (18/18) expressed Sox2 at variably high levels (Fig. 1C). We then examined
osteosarcoma cell lines established from p53-/-Rb-/- conditional (bone-specific) knockout
mice (Berman et al 2008, Walkley et al 2008). Such tumors arising in the conditional mice
mimic the human malignancy with respect to gene expression and metastasis (Walkley et al
2008). As shown in Figure 1B, Sox2 is highly expressed in four independent murine
osteosarcoma-derived cell lines (mOS), as compared to wild type (WT) primary osteoblasts
both at the mRNA and protein levels. Since the murine osteosarcoma cell lines display the
high levels of Sox2 expression observed in human cell lines and their origin and history are
well controlled, we have used these cells to carry out the subsequent experiments reported
here.
Sox2 expression is induced by FGF signaling in preosteoblasts (Mansukhani et al 2005). To
determine whether FGF signaling might account for the high Sox2 expression in
osteosarcomas, we used the pan-FGFR inhibitor PD173074 to block FGF signaling in these
cells (Beenken and Mohammadi 2009). Increasing doses of PD173074 block FGF signaling,
as measured by a decrease in phosphorylated FRS2 (a downstream adaptor protein highly
specific to FGF signaling) and Erk1 and 2. Sox2 expression decreased in a dose-dependent
manner 48 hours after treatment with 10μM PD173074 (Fig. S1) and cell proliferation was
retarded. These findings indicate that the high Sox2 expression in osteosarcoma cells may be
dependent on FGF signaling, and suggested that reducing Sox2 expression affects
osteosarcoma cell proliferation.
Sox2 is required for osteosarcoma cell survival, in vitro transformed properties and tumor
formation
To determine the role of Sox2 in osteosarcoma cells, we knocked down Sox2 expression
using shRNA against Sox2 in the four murine osteosarcoma lines whose genotypes are
indicated in Fig.2B. Cells were infected with pBABE-hygro retrovirus expressing the two
Sox2-specific shRNAs or a scrambled shRNA control, and selected for hygromycin
resistance.
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tAs shown in Figure 2A, two different shRNAs against Sox2 substantially reduce Sox2
expression. Osteosarcoma cells infected with high titer retroviruses expressing the Sox2-
specific shRNAs showed a drastically reduced (80-90%) ability to form colonies in the
presence of hygromycin (Fig. 2B). However hygromycin resistant, Sox2-shRNA stably
expressing cells could be easily isolated. These cells had low levels of Sox2 protein and
were compared with cells expressing scrambled shRNA for ability to proliferate as well as
for in vitro properties of transformation, including growth in soft agar and ability to migrate
and invade (Fig. 2C-E). These results were reproduced an at least two other murine
osteosarcoma cell lines. Sox2 depletion slightly decreased proliferation rate (Fig.S2A-B)
with concomitant upregulation of the CDK inhibitors p16 and p27, but these cells proliferate
well without evidence of increased apoptosis or senescence (Fig. S2C, D). On the other
hand, the growth of osteosarcoma cells in soft-agar was drastically impaired by Sox2
depletion. Sox2 downregulation also dramatically decreased migration and invasion. (Fig.
2C-E). As the modest decrease in proliferation in the Sox2-depleted cells was not sufficient
to explain these effects, we examined whether Sox2 depletion alters attachment of cells to
substratum. We employed an in vitro adhesion assay (Douglas et al 2008) and determined
that cells expressing Sox2 shRNAs do not show altered adherence to substratum (Fig.S3).
These results indicate that depletion of Sox2 markedly reduces the in vitro transformed
phenotype of osteosarcoma cells. Although the data shown are only for the mOS-482 cells,
these results were replicated in the mOS-379 and mOS-202M cell lines.
We tested the ability of the parental osteosarcoma cells, cells expressing scrambled shRNA
or Sox2 shRNAs to form tumors in immunocompromised NOD/SCID mice. While parental
cells and cells expressing scrambled shRNA readily implanted and formed tumors within
two weeks, Sox2 knockdown cells failed to form palpable tumors within 10 weeks. (Fig.2F).
Notably, after about 12 weeks 5/16 of the animals injected with the Sox2 knockdown cells
developed tumors that grew progressively. When these tumors were excised and examined
for Sox2 expression, they all showed high levels of Sox2 protein expression (Fig. 2F). The
absence of detectable Rb and p53 protein expression in the tumor lysates confirmed that the
tumors were derived from the originally injected p53-/- Rb-/- cells (Figure S4). Thus down-
regulation of Sox2 attenuates in vivo tumor formation by osteosarcoma cells, and cells that
could form tumors had reacquired high Sox2 expression.
Sox2 marks a population of osteosarcoma stem cells
As previously mentioned, osteosarcomas may contain a sub-population of tumor initiating
stem cells (Gibbs et al 2005). The murine osteosarcoma cell lines that we have used support
this notion as they contain multipotent cells that are capable of differentiating into different
lineages such as the adipocytic and osteoblastic lineage (Berman et al 2008) as well as a
population of Sca-1 positive cells, that appears to represent the tumor-initiating fraction
(Walkley et al 2008). Futhrmore, sphere-forming osteosarcoma cells (also referred to as
sarcospheres or osteospsheres) have increased tumorigenic capacity (TICs) (Rainusso et al
2011). We grew osteosarcoma cells in suspension in defined serum-free medium and
determined that they are capable of forming osteospheres, spherical colonies forming in non-
adherent conditions that are generally considered to represent self-renewing, stem-like cells
(Gutierrez et al 2008, Rainusso et al 2011). These osteospheres are enriched for Sox2 and
Sca-1, a stem cell antigen of the hematopoietic system. Osteospheres also exhibit low
expression of osterix (OSX), a marker of more mature osteoblasts (discussed later). We
labeled the cell lines with antibodies to Sca-1 and Sox2 and analyzed the proportion of cells
expressing either antigen by flow cytometry. As shown in figure 3A, the majority of the
cells co-expressed both Sca-1 and Sox2, consistent with Sca-1 expression marking a
population of Sox2 positive cells. Since all cell expressing high levels of Sca-1 antigen were
also strongly Sox2 positive, we sorted two of the cell lines into Sca-1HI and Sca-1LO
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tfractions by magnetic separation. The purity of each fraction was determined by flow
cytometry for Sca-1 (Fig. S5) and Western analysis for Sox2 (Fig.3B). After verifying that
each fraction indeed consisted of Sca-1HI Sox2HI and Sca-1LO Sox2LO cells, these fractions
are hereafter referred to as Sca-1HI Sox2HI and Sca-1LO Sox2LO cells. Each live cell fraction
was plated to test a) the ability to form osteospheres and b) ability to differentiate into the
osteoblastic and adipogenic lineage. The Sca-1HI Sox2HI fraction contained a higher
proportion of cells capable of forming osteospheres (Fig.3C). To confirm that fewer Sca-1HI
Sox2HI cells can form spheres, we performed a limiting dilution assay for sphere formation.
While the Sca-1HI Sox2HI cells could form spheres at a frequency of 1/18, this was
decreased to 1/50 in the Sca-1LO Sox2LO cells (Table 1). Additionally, while their
osteoblastic differentiation ability was strongly reduced as compared to the Sca-1LO Sox2LO
fraction, the Sca-1HI Sox2HI fraction produced significantly more adipocytes than the
Sca-1LO Sox2LO fractions (Fig. 3D). This result indicates that Sox2 expression marks a
population of Sca-1 positive cells that have a low capacity for osteoblastic differentiation,
but have maintained the ability to enter the adipocytic fate.
A property of stem cells is the ability to undergo symmetric as well as asymmetric division,
generating either undifferentiated or both undifferentiated and differentiated daughter cells.
To confirm that the Sca-1HI Sox2HI fraction represented a stem cell population, we
propagated doubly purified populations (Fig.S5) of Sca-1HI and Sca-1LO cells for several
passages, and determined the proportion cells with high or low Sca-1 expression as well as
high or low Sox2 at each passage. While the Sca-1LO fraction remained stable over 7
passages, the Sca-1HI fraction generated an increasing proportion of Sca-1LO cells, that were
also low in Sox2 expression, indicating that the Sca-1HI Sox2HI cells are capable of self-
renewal as well of generating Sca-1LO Sox2LO progeny (Fig. 3E). As the Sca-1HI Sox2HI
cells grow somewhat faster than the Sca-1LO Sox2LO cells, it is unlikely that the Sca-1LO
Sox2LO cells are repopulating the Sca-1HI Sox2HI fraction (Fig. S6E).
To test whether Sox2 is required to maintain a subpopulation of self-renewing osteosarcoma
cells, we determined the ability of the control and Sox2-shRNA expressing cells to form
osteospheres. As shown in Figure 4, osteosarcoma cells expressing Sox2 shRNAs have
reduced Sca-1 expression and show greatly reduced ability to form osteospheres (Fig. 4B).
A similar reduction in sphere-forming ability is also seen in human osteosarcoma cells in
which Sox2 has been depleted. Both Saos-2-LM7 cells (an established metastatic
osteosarcoma cell line) and OS-NYU1 (primary osteosarcoma-derived cells from a fresh
tumor biopsy), infected with a human Sox2shRNA, show decreased Sox2 expression and
reduced sphere formation (Fig. 4C and D), confirming that the requirement for Sox2 is not
limited to murine osteosarcoma cells. To strengthen the notion that high levels of Sox2
expression correlate with the ability of cells of the osteoblast lineage to form osteospheres,
we over-expressed Sox2 in murine primary osteoblasts using lentivirus vectors, and found
that Sox2 over-expression is sufficient to enhance osteosphere formation (Fig. S6).
Additionally, over-expression of Sox2 was sufficient to reduce osteogenic and increase
adipogenic differentiation (Fig. S6). These gain-of-function studies in primary osteoblasts
produced the opposite effects seen by the depletion of Sox2.
We then determined the ability of the parental and Sox2 knockdown osteosarcoma cells to
differentiate into osteoblastic and adipocytic lineages (Fig.5). Parental osteosarcoma cells, or
those expressing scrambled shRNAs, are impaired in their ability to differentiate into
osteoblasts (Fig. 5A). However, the Sox2 shRNA-expressing cell lines rapidly differentiate
into mature osteoblasts, as shown by an increase expression of alkaline phosphatase and
osteocalcin (Fig.5A), as well as Runx2 and OSX (not shown). Like the Sca-1LO Sox2LO
cells, these Sox2-depleted cells are impaired in their ability to enter the adipocytes lineage,
as revealed by the absence of Oil Red O positive granules (Fig. 5B). Adipogenesis can occur
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tin the parental cells, as shown by the presence of Oil Red O stained lipid granules, and
expression of the adipocyte-specific genes PPARγ and AP2 (Fig.5B). Together the results
presented in this section indicate that high Sox2 expression marks a population of Sca-1
positive stem-like cells and is required for their maintenance. Furthermore Sox2
downregulation results in a lineage shift in the differentiation ability of osteosarcoma cells,
such that cells with high Sox2 expression preferentially differentiate into the adipogenic
pathway, while Sox2 depleted cells only undergo osteogenic differentiation.
Sox2 depletion in osteosarcoma cells results in activation of Wnt signaling
Wnt signaling is a critical pathway for proper bone formation, and stimulates osteoblast
lineage commitment and maturation (Krishnan et al 2006, Milat and Ng 2009). Sox2 plays a
role in the antagonistic effect of FGF on the Wnt pathway (Ambrosetti et al 2008,
Mansukhani et al 2005). Therefore, we analyzed Wnt signaling in control and Sox2 knock
down osteosarcoma cells. Activation of Wnt signaling results in stabilization and nuclear
translocation of β-catenin, that together with TCF/LEF factors regulates Wnt-target genes
(Clevers 2006). We first assessed the levels of active β-catenin (ABC) (ABC - β-catenin that
is unphosphorylated at critical serine and threonine residues and hence, resistant to
proteasomal degradation) (van Noort et al 2002). As shown in Figure 6A, ABC levels are
strongly increased in cells expressing Sox 2-shRNAs, suggesting that Wnt signaling is active
in these cells. We then established stable cell lines expressing a Wnt-responsive
TOPFLASH reporter (Ambrosetti et al 2008), and determined whether basal Wnt signaling
was higher in the cells expressing Sox2-shRNA. We found that the basal levels of
TOPFLASH reporter activity were much higher in cells expressing Sox2 shRNAs, as
compared to the control cells. In addition, these cells responded more strongly to exogenous
Wnt3A stimulation (Fig 6B). Osteoblast-specific Wnt targets, such as Axin2, Timp3 and
CTGF (Ambrosetti et al 2008), were also up-regulated in Sox2- shRNA-expressing
osteosarcoma cells (Fig. 6C). We established osteospheres from osteosarcoma cells
expressing the Wnt reporter. As expected, Sox2 expression was dramatically increased in
osteospheres as compared to the total adherent cell population, while the levels of Runx2
and Osterix, markers of more mature osteoblasts, were decreased (Fig. 6E and F). The
activity of the Wnt reporter was strongly decreased in the osteospheres (Fig. 6D). Together
these results indicate that Wnt signaling is repressed in osteosarcoma cells expressing Sox2
and that Sox2 downregulation results in increased Wnt signaling. While we cannot
conclusively prove that the increased Wnt signaling requires inhibition of Sox2 expression
or function, we observed that activation of Wnt signaling in osteoblasts or osteosarcoma
cells induces slow but very significant downregulation of Sox2 protein expression (Fig.7A).
Thus, high Sox2 expression is accompanied by reduced Wnt signaling while activation of
the Wnt pathway results in low Sox2 expression, suggesting that activation of Wnt signaling
antagonizes the effect of Sox2 in maintaining osteosarcoma cells in an undifferentiated
stem-like state. A model depicting the regulation of osteosarcoma cells self-renewal and
differentiation by Sox2 and Wnt is shown in Fig. 7B.
Discussion
Osteosarcomas are tumors of mesenchymal origin that are derived from immature
osteoblasts. We show here that Sox2 expression is up-regulated in human and murine
osteosarcoma cell lines, and in primary human osteosarcomas. Sox2 knock-down markedly
reduces in vitro transformed properties, including, migration, invasion and colony formation
in soft agar. Interestingly, Sox2-depleted osteosarcoma cells show a dramatic decrease in
osteosphere formation and expression of the Sca-1 stem cell antigen, accompanied by
enhanced differentiation into mature bone forming osteoblasts with activation of Wnt
signaling. Consistent with these findings, cells depleted of Sox2 fail to form tumors in
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tmurine xenografts. These data identify a critical role of Sox2 in the maintenance of a
population of self-renewing, stem-like osteosarcoma cells.
Osteosarcomas overexpress Sox2
As Sox2 is highly expressed in several osteosarcoma cell lines we reasoned that increased
FGF signaling may be responsible, at least in part, for high Sox2 expression in these cells.
Indeed, we found that inhibition of FGF signaling decreased Sox2 expression and
proliferation. Sox2 has been identified as an oncogene and is amplified in squamous cell
carcinoma of the lung and esophagus (Bass et al 2009, Xiang et al 2011). Genomic analysis
of osteosarcomas does not indicate amplification of the Sox2 gene and we have not detected
increased expression of FGFR1 and 2 genes in those cells. It is possible that the relatively
high Sox2 expression in osteosarcomas reflects their higher content of immature, stem-like
cells and that FGF signaling is kept active by an autocrine mechanism sustained by an
endogenously produced FGF ligand. The high expression of Sox2 in those cells is not due to
loss of p53 function, since ectopic expression of wild type p53 does not affect Sox2
expression in our murine osteosarcoma cell lines.
Sox2 regulates osteosarcoma cell tumorigenesis and differentiation
We have shown that Sox2 is an essential gene for osteoblast survival and self-renewal in
culture, where it exerts multiple functions, including direct transcriptional regulation and
inhibition of osteoblast differentiation (Basu-Roy et al 2010, Mansukhani et al 2005). The
results shown here demonstrate that Sox2 is also required for self-renewal and
tumorigenicity of osteosarcoma cells. Acute Sox2 downregulation results in considerable
loss of colony-forming ability in tumor-derived murine cell lines, but differently from what
observed in normal osteoblasts, that enter a non–proliferative senescent-like state following
Sox2 inactivation (Basu-Roy et al 2010, Mansukhani et al 2005), osteosarcoma cells with
strongly reduced Sox2 expression can be easily isolated and propagated in culture. Murine
osteosarcomas contain a population of cells with high Sox2 and Sca-1 expression, as well as
cells with low levels of Sox2 and Sca-1. Sox 2 highly expressing osteosarcoma cells are
tumorigenic, form osteospheres, express the Sca-1 antigen, are inhibited in osteogenic
differentiation, and are capable of symmetric and asymmetric division. In contrast, cells with
reduced Sox2 expression, whether spontaneously occurring (Sca-1LO Sox2LO) or created by
Sox2 knock-down, have reduced ability to form osteospheres, do not express Sca-1, and
readily undergo osteogenic differentiation. Importantly they do not appear to be capable of
generating Sca-1HI Sox2HI dedifferentiated cells.
Osteosarcoma cells with reduced Sox2 expression fail to form tumors in xenograft assays.
Interestingly, the few tumors that arose with long latency in animals injected with Sox2-
depleted cells had reacquired high levels of Sox2. This is likely because of loss of the
shRNA plasmid in the absence of positive selection, thus strengthening the notion that Sox2
is required for the tumorigenic phenotype. In addition, Sox2-depleted cells exhibit reduced
Sca-1 expression, increased expression of the cell cycle inhibitors p16 and p27, and readily
differentiate into mature osteoblasts. Disruption of p27 function has been reported in
osteosarcomas (Thomas et al 2004). Although the distinction may be semantic, we do not
think that Sox2 is a canonical osteosarcoma oncogene, but rather that its function is essential
for self-renewal of osteoblast precursors. Thus its inactivation would lead to the reduction of
a subpopulation of stem-like cells or promote a terminally differentiated state that is
incompatible with sustained proliferation.
Together, the data presented in this report strongly support the hypothesis that Sox2 marks a
population of tumor-initiating osteosarcoma cells with stem cell properties and is necessary
for their renewal and tumorigenic ability. In apparent contrast with this notion however,
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tSox2 highly expressing cells are a sizable portion of our osteosarcoma cell populations,
while cancer stem cells are generally thought to represent a minority of the tumor cells. This
prevailing notion however mostly derives from studies of hematologic malignancies, but
even in this case there are exceptions (Adams et al 2008, Kelly et al 2007, Rosen and Jordan
2009). For solid tumors several reports have identified a large portion (up to 90%) of tumor
initiating cells with stem-like properties (Boiko et al 2010, Gangemi et al 2009, Gong et al
2010, Rosen and Jordan 2009, Takenobu et al 2011). Furthermore, in our case, the high
proportion of stem-like cells is to a good extent the result of propagation in culture, as
shown in the original characterization of the murine osteosarcomas used in the present
studies (Walkley et al 2008). This report showed quite clearly that the proportion of Sca-1HI
cells in the tumors (that we have shown to correspond to the Sox2HI population) increases
substantially with establishment and further propagation in tissue culture. The definition or
concept of “cancer stem” cells has been the subject of considerable debate and is still open
to different interpretations (Rosen and Jordan 2009). Our work identifies Sox2 as a
transcription factor which marks and maintains a distinct cell population in osteosarcomas
that has stem cell properties and is responsible for their tumorigenic potential. A recent
study reported expression of Sox2 in sphere-forming cells from human sarcomas (Tirino et
al 2011).
Although the mechanisms that disrupt osteogenic differentiation are not well understood,
our data suggest that Sox2 is a key player in this process. Sox2 downregulation promotes
osteoblast differentiation, while restricting entry to the adipogenic pathway. Few
determinants of mesenchymal stem cell fate are known. Taz and Rb have been shown to
play a role in the balance of bone versus adipocyte lineages (Berman et al 2008, Calo et al
2010, Hong and Yaffe 2006)., Our findings suggest that Sox2 levels may be important for
fate choices in the mesenchymal lineage. High Sox2 appears to favor the adipogenic fate,
whereas low Sox2 may favor the osteoblastic fate. As discussed later, this hypothesis fits
with the antagonism of Sox2 with the Wnt pathway which has pro- osteoblastic and anti-
adipogenic properties (Takada et al 2009).
Sox2 antagonizes Wnt signaling in osteosarcomas
An extensive body of evidence indicates that Wnt signaling promotes osteoblast
differentiation and function (Krishnan et al 2006), and we had previously shown that Sox2
played a role in the antagonistic effect of FGF signaling in inhibiting Wnt-induced
osteoblast differentiation (Ambrosetti et al 2008). The mechanism by which Sox2 inhibits
Wnt signaling is complex. While it clearly involves binding of Sox2 to β-catenin, it may
also include transcriptional regulation of several Wnt pathway genes. Following Sox2
downregulation in osteosarcoma cells, we found a striking increase in Wnt pathway activity,
including increasing amounts of active β-catenin, activation of endogenous Wnt target
genes, and increased activity of a Wnt-reporter. Furthermore, inactivating phosphorylation
of GSK3β, that would result in increased abundance of active β-catenin, was significantly
increased in Sox2 knock-down cells. While these findings confirm our previous
identification of Sox2 as an antagonist of Wnt signaling in osteoblasts (Mansukhani et al
2005), they are in contrast with the notion that increased Wnt signaling promotes
osteosarcomagenesis. The pro-tumorigenic role of Wnt signaling is well-established in
epithelial cancers (Clevers 2006), but its role in tumors of mesenchymal origin is
controversial. Although the inactivation of a Wnt inhibitor has been linked to radiation-
induced osteosarcoma (Kansara et al 2009), other groups have found that Wnt signaling is
down-regulated in osteosarcomas (Cai et al 2010, Cleton-Jansen et al 2009). Wnt signaling
could therefore be active in less aggressive tumors, but does not appear to play a pro-
tumorigenic role in the osteosarcoma model we studied, where it clearly correlates with a
reversal of transformed growth properties.
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tSox2 appears to maintain osteosarcoma cells in a self-renewing state, in part through
inhibition of the pro-differentiation Wnt pathway. The notion that Wnt signaling plays a
tumor suppressive role in these tumors is not limited to osteosarcomas, but has been
proposed for other mesenchymal tumors, such as malignant fibrous histocytoma, where
establishment of Wnt signaling prevents differentiation (Matushansky et al 2007). Our
finding that Sox2 might play a critical role in tumors of mesenchymal origin is also
consistent with a similar finding in Ewings' sarcoma, where Sox2 maintains a stem cell-like
signature (Riggi et al 2010).
Thus, more generally, Sox2 may be responsible for maintaining self-renewal of a
subpopulation of mesenchymal tumor cells. Interestingly, the effect of Sox2 depletion on in
vitro tumorigenic self-renewing properties is apparent in cells that lack both Rb and p53,
indicating that Sox2 may be an effective target in cancers that lack these tumor suppressors.
The mechanism(s) by which Sox2 maintains self-renewal in osteosarcoma cells are probably
complex but likely result mainly from its function as a direct transcriptional regulator. Our
preliminary analysis of the gene expression profiles of parental and Sox2 depleted
osteosarcoma cells shows that a number of genes are downregulated in the Sox2 depleted
cells. The ability of Sox2 to inhibit canonical Wnt signaling, that does not require its DNA
binding domain (Ambrosetti et al 2008, Mansukhani et al 2005), may also play an important
role. Sox2 could also directly activate the expression of specific inhibitors of the Wnt
pathway, such as APC. In addition, Sox2 protein levels are down-regulated by Wnt
signaling. This finding may fit with a recent report that Sox2 could be a target of GSK3β in
Wnt-dependent protein metabolism (Taelman et al 2010).
In short, our study highlights the role of Sox2 in the maintenance of self-renewing cells in
osteosarcoma and identifies the Wnt pathway as a potential anti-tumorigenic pathway in
these tumors. The osteosphere forming population in osteosarcomas has been reported
recently to be refractory to chemotherapeutic drugs (Fujii et al 2009). This observation may
provide an explanation for the poor response of osteosarcomas to chemotherapy. Blocking
Sox2 function in osteosarcoma may be considered a basis for novel and effective therapeutic
strategies for the treatment of these tumors.
Materials and Methods
Cell culture
The human osteosarcoma cell lines, U-2OS, MG63 and HOS were obtained from the
American Type Culture Collection. The OS-187 cells were a gift from Dr. Nancy Gordon
from M.D. Anderson Cancer Center, TX The OS-99-1 cells were obtained from Dr. Shiela
Nielsen-Preiss, University of Montana, Missoula, MO (Gillette et al 2008). The parental
Saos-2 cells and the Saos-2-LM7 cells that are a metastatic variant of Saos-2 were provided
by Dr. Eugenie Kleinerman, M. D. Anderson Cancer Center, TX (Jia et al 1999). The
murine osteosarcoma cells used in this study (mOS-482, mOS-379, mOS-648 and
mOS-202M) were derived from spontaneous osteosarcomas and isolated as previously
described (Walkley et al 2008). All cells were maintained in DMEM supplemented with
10% fetal bovine serum. Human osteosarcoma tissue samples were obtained from
INGENEX (Super Biochip) and New York University Medical Center Tissue Acquisition
Banking Services (TABS). These samples were obtained following the NIH guidelines for
research on human specimens. Fresh human osteosarcoma tissue was obtained from TABS.
Tumor tissues were minced asceptically after diagnostic biopsy and digested in 2U/ml
dispase for 1 hour at 37 °C. Cells were grown in RPMI medium supplemented with 10%
fetal bovine serum for all experiments.
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tSox2 knockdown and over-expression
pBabe-Hygro-retrovirus- vector containing scrambled or Sox2-specific shRNA (described in
(Basu-Roy et al 2010) was used to infect four independent osteosarcoma cell lines. For
colony formation assay, murine osteosarcoma cells were plated at a density of 5000cells/
well in 6-well plates and infected for 24 hours in the presence of 8 μg/ml polybrene at an
MOI of ∼ 50. Following infection, colonies were selected in 200 μg/ml Hygromycin B for
7-10 days and stained with Crystal Violet. For selection of cells expressing Sox2 shRNA,
cells were infected as in the colony forming assay and selected for 14 days in 200 μg/ml
Hygromycin B. Pools of cells expressing scrambled or Sox2 shRNA were used in all
experiments. For Sox2 over-expression studies, primary osteoblasts were infected with a
lentivirus expressing full length human Sox2 cDNA as described before (Basu-Roy et al
2010).
Establishment of Wnt reporter osteosarcoma cell lines
Osteosarcoma cell lines expressing scrambled or Sox2 shRNA were transfected with a 8×
TOP-Luciferase construct that is responsive to Wnt-dependent induction in osteoblasts
(described previously in (Ambrosetti et al 2008). Stable cell lines expressing both shRNA
and Wnt reporter were selected in the presence of 200 μg/ml Hygromycin B and 500 μg/ml
G418. Pools were analyzed based on their responsiveness to Wnt 3A conditioned medium.
In vitro transformation and in vivo tumorigenicity assay
Cells expressing scrambled or Sox2 shRNA were used in these assays. In vitro migration,
invasion and soft agar growth were assessed as described (Cantiani et al 2007). To assay for
cell migration, 105 osteosarcoma cells were plated in Transwell chambers (Costar). Cells
(105) in serum-free DMEM were seeded in the upper compartment, whereas DMEM plus
10% FBS was placed in the lower compartment of the chamber. Cells migrated to the lower
side of the membrane was counted after crystal violet staining. Experiments were done in
triplicate. To assay for cell invasion, cells (5 × 105) were seeded in the upper compartment
of Biocoat Matrigel invasion chambers (BD Biosciences). In these chambers, the upper
compartment is coated with Matrigel and migrating cells must pass through the Matrigel
layer. This assay measures the ability of cells to degrade the Matrigel layer before migrating
to the lower compartment. Assay was done according to the manufacturer's instructions
similar to cell migration. All experiments were made in triplicate. For soft agar assays to
assess anchorage-independent growth, 10,000 cells were suspended in semi-solid medium
(DMEM with 10% FBS and 0.33% agarose) with a 0.5% agarose underlay, in 6-well plates
and incubated at 37°C. Colonies were counted after 10-12 days.
For assay of in vivo tumorigenicity, 5 × 106 cells were injected subcutaneously into NOD/
SCID mice. Tumor growth was monitored bi-weekly and tumor volume was measured with
an electronic caliper using the formula Tumor Volume (TV) = L * W2 * Π / 6. All
tumorigenesis studies were performed at the Antitumor Assessment Facility of Memorial
Sloan Kettering Cancer Center under IACUC Approved Protocol Number A3311-01.
Isolation of Sox2-Sca-1 double-positive cells
Flow cytometry of intracellular Sox2 and membrane Sca-1 double-labeled cells was carried
out as follows. Phycoerythrin (PE)-conjugated Sca-1 and anti-rabbit Alexa Fluor 488
secondary antibody were from Invitrogen, Carlsbad, CA. Sox2 polyclonal antibody used for
flow cytometry was obtained from Millipore, Billerica, MA. For labeling 1 × 106 cells, 0.1
μg/ml of PE-Sca-1 antibody or isotype control was used. Briefly, cells were washed in cold
FACS buffer (5% FBS in PBS with 0.02% sodium azide). Cells were incubated on ice with
diluted Sca-1 antibody for 20 minutes and washed three times with FACS buffer. For Sca-1
Basu-Roy et al. Page 10
Oncogene. Author manuscript; available in PMC 2012 November 03.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tstaining, cells were then resuspended in 4% paraformaldehyde (PFA) and analyzed by flow
cytometry. For intracellular staining for Sox2, cells were first stained for surface Sca-1 as
described above. After washing, cells were permeabilized in 1% saponin in FACS buffer on
ice for 20 minutes, followed by incubation with 0.5 μg/ml of either Sox2 or rabbit IgG as
isotype control on ice for 30 minutes. Cells were then washed three times with
permeabilization buffer, followed by incubation with a 1:400 dilution of the anti-rabbit
secondary antibody in permeabilization buffer. After washing three times with
permeablization buffer, cells were resuspended in PFA for flow cytometric analysis. Data
were collected on a FACScan flow cytometer using CellQuest software and analyzed using
FlowJo software (TreeStar, Ashland, OR). 30,000–50,000 events were collected per sample.
Osteosarcoma cells were fractionated into Sca-1HI and Sca-1LO cells using the Sca-1 Cell
Separation Kit (Stem Cell Technologies, Vancouver, Canada) as described by the
manufacturer's instructions. Fractionated cells were used immediately for all experiments.
Osteosphere Assay and Limiting Dilution Analysis
Osteosphere assay was carried out as described (Gutierrez et al 2008). Briefly, 1000 cells
were plated in triplicate in 24-well Corning ultra-low attachment plates for 7-10 days in
N2B27 defined serum free medium. Osteospheres were collected by sieving through a 40
μM strainer. RNA was extracted from the spheres for gene expression analysis. Spheres
were counted in each plate using a Leica MZ12 inverted microscope. For limiting dilution
analysis of sphere-forming cells, cells were plated at limiting dilutions in 96-well plates in
N2B27 defined serum free medium for 10 days. Wells were scored as positive or negative
based on the presence or absence of sphere, and data was analyzed using ELDA software
(Hu and Smyth 2009).
Gene expression analysis by quantitative real-time RT-PCR and Western Blotting
mRNA was prepared using Trizol Reagent (Invitrogen, USA). Reverse transcription and
real-time PCR analysis was carried out as previously described (Mansukhani et al 2005)
using specific primers. Actin was used as a normalization control. Antibodies used in the
study were Sox2 (Cell Signaling, Danvers, MA), active β-catenin or ABC (Millipore,
Billerica, MA) and γ-tubulin (Sigma, St. Louis, MO).
Osteogenic and Adipogenic Differentiation
Cells were plated at a density of 50,000 cells/well of 24-well plates or 0.5 × 106 cells/well of
6-well plate. For osteogenic differentiation, cells were incubated in the presence of 10 mM
β-glycerol phosphate and 100 μg/ml ascorbic acid for the indicated times. Differentiation
was assessed by staining for alkaline phosphatas. For adipogenic differentiation, cells were
incubated in the presence of 100 nM dexamethasone, 250 μM Iso-butyl-methyl-xanthine
(IBMX), 100 μM indomethacin and 10 μg/ml insulin. Adipocytes were detected by staining
with Oil Red O.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Sox2 is highly expressed in human and murine osteosarcomas
Sox2 mRNA (left) and protein expression (right) in human (A) and murine (B)
osteosarcoma cell lines. Quantitative RT-PCR for mRNA levels and Western blot of Sox2
protein in the indicated cell lines. hFOB, Normal Fetal Human Osteoblast; WT osteoblasts,
wild type murine primary calvarial osteoblasts.
(C) Sox2 expression in human osteosarcoma tissue. Immunohistochemistry on paraffin-
embedded human osteosarcoma tissue samples using a polyclonal antibody against Sox2
(Magnification 10×). Representative images of osteosarcoma samples are shown. Higher
magnification (40×) at which nuclear Sox2 staining is evident is shown. Secondary antibody
alone was used as a negative control. We examined a total of 18 samples. Tumors were
identified as Sox2-positive when nuclear staining was present in more than 50% cells per
field. All samples were scored positive by these criteria.
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tFigure 2. Sox2 depletion decreases transformation properties and tumorigenesis
(A) Sox2 protein expression in osteosarcoma cells stably expressing Sox2 shRNA.
Western blot of mOS-482 osteosarcoma cells expressing scrambled (sc) shRNA or shRNAs
against Sox2 were analyzed by immunoblotting. Tubulin was used as a loading control.
(B) Colony formation. Osteosarcoma cells infected with either scrambled (sc) or Sox2
shRNA viruses were selected in Hygromycin B for 7-10 days. Colonies were counted
following staining with Crystal Violet. Representative plates of mOS-482 cells are shown.
Table shows genotypes and colony counts from four independent cell lines.
(C) Soft Agar Colony Formation; (D), Migration and (E) Invasion. mOS-482 cells
expressing sc or Sox2 shRNA were analyzed in the indicated assays as described in
Materials and Methods. All experiments were performed in at least two independent cell
lines. Results shown are an average of triplicate plates. * = p<0.05
(F) Tumorigenicity assay: Tumor-forming ability of osteosarcoma cell lines (mOS-482)
expressing either scrambled or Sox2 shRNAs, was measured in NOD/SCID mice. Injection
of 1 × 106 cells gave similar results (not shown). Tumor volume was monitored and
measured bi-weekly. Difference between groups was measured by ANOVA. * = p<0.05
The inset shows a western blot of Sox2 protein expression in the injected cells and isolated
tumors from either scrambled or long latency tumors arising from cells expressing Sox2
shRNAs.
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tFigure 3. Sox2 marks a population of Sca-1 positive, multipotent osteosarcoma stem cells
(A) Flow cytometric analysis of Sox2 and Sca-1 doubly-labeled osteosarcoma cells.
Osteosarcoma cells (mOS-482) were labeled to detect membrane Sca-1 (PE- Sca-1,
Phycoerythrin-Sca-1 conjugated antibody) and intracellular Sox2 (Sox2 polyclonal antibody
followed by Alexa Fluor 488 conjugated secondary antibody). Forward scatter-Side scatter
(FSC-SSC) profile shows that 90% cells were viable (Fig. S4) and was used for anaysis.
Sca-1HISox2HI population is indicated in top right quadrant. The percentage of
Sca-1HISox2HI population from three independent cell lines is shown in the adjoining Table.
(B) Sox2 protein expression in Sca-1HI and Sca-1LO fraction. mOS-482 cells were
separated into Sca-1HI and Sca-1LO cells using Sca-1 magnetic bead separation. Western
blot of Sox2 expression in the total adherent population and the two fractions is shown.
(C) Osteosphere Assay. Equal numbers of cells from Sca-1HI and Sca-1LO fractions from
mOS-482 cells were plated in suspension culture in triplicate. Spheres were counted after 10
days. Each experiment was repeated at least twice. Results from a representative experiment
are shown. * = p<0.05
(D) Osteogenic and Adipogenic Differentiation Assay. Sca-1HI and Sca-1LO fractions
from mOS-482 cells were plated in either osteogenic or adipogenic medium. Osteogenic
differentiation was detected using alkaline phosphatase staining. Results from representative
plates at the indicated time period are shown. Adipogenesis was detected by Oil Red O
staining of cells induced for 15 days (magnification 100×).
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t(E) Serial propagation of Sca-1HI and Sca-1LO fractions. Sca-1HI and Sca-1LO fractions
from mOS-482 cells were doubly purified by magnetic bead and FACS. Each fraction was
plated separately and serially passaged. After labeling for both Sox2 and Sca-1, the
proportion of cells that were doubly positive (Sca-1HI Sox2HI or Sca-1LOSox2LO) at each
passage was determined by flow cytometry.
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tFigure 4. Sox2 down-regulation decreases the stem cell population in murine and human
osteosarcomas
(A) Surface Sca-1 expression is reduced in Sox 2-depleted cells. mOS-379 cells
expressing either scrambled or Sox2 shRNA were stained with a PE-conjugated anti-Sca-1
antibody and analyzed by flow cytometry. Mean fluorescence intensity (MFI) of the
indicated cells is plotted. Y axis = % of Max (Percentage of Maximum MFI). X axis = rIgG-
PE (rat-PE-conjugated-anti-Sca-1)
(B) Osteosphere Assay. Equal numbers of cells expressing scrambled or Sox2 shRNA were
plated in suspension culture in triplicate. Spheres were counted after 10 days. Each
experiment was repeated at least twice. Results from a representative experiment are shown.
* = p<0.05. Similar results were obtained with the mOS-682 and mOS-202M cell lines.
(C) and (D) Western Analysis ad Osteosphere Assay in human osteosarcoma samples.
Saos-2-LM7 (Figure 4C) or primary osteosarcoma cells from fresh biopsy (OS-NYU1)
(Figure 4D) cells expressing either scrambled or human Sox2 shRNA were analyzed for
Sox2 expression by Western analysis. For osteosphere assay, equal numbers of cells
expressing scrambled or human Sox2 shRNA were plated in suspension culture in triplicate.
Spheres were counted after 10 days. Each experiment was repeated at least twice. Results
from a representative experiment are shown. * = p<0.05.
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tFigure 5. Sox2 down-regulation increases osteoblastic differentiation of murine osteosarcoma
cells
(A) Osteoblastic differentiation. mOS-379 cells expressing scrambled or Sox2 shRNA
were plated in osteogenic for the indicated time periods. Differentiation was assessed using
alkaline phosphatase staining. Results from representative plates at the indicated time period
are shown. For gene expression analysis, real-time quantitative PCR analysis using primers
for osteocalcin at the indicated times is shown. All values are normalized to actin and are
expressed relative to expression in uninduced cells at Day 0.
(B) Adipogenic differentiation. mOS-379 cells expressing scrambled or Sox2 shRNA were
plated in adipogenic medium for 15 days. Differentiation was measured using Oil Red O
staining (magnification 100×). For gene expression analysis, real-time quantitative PCR
analysis using primers for PPARγ and aP2 at the indicated days. All values are normalized
to actin and are expressed relative to uninduced cells at Day 0.
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tFigure 6. Sox2 depletion leads to activation of Wnt signaling in osteosarcoma cells
(A) Activated β-catenin (ABC) protein expression. Immunoblot of mOS-379 cells
expressing either scrambled or Sox2 shRNA with anti-ABC antibody. γ- tubulin was used
as a loading control.
(B) Wnt reporter activity. Relative TOPFLASH luciferase reporter activity in mOS-379
cells expressing scrambled or Sox2 shRNA. Basal (black bars) or Wnt 3A stimulated (gray
bars) activity at 48 hours was measured and normalized to total protein.* = p<0.05
(C) Wnt target gene expression. Real-time quantitative PCR analysis of CTGF, Axin and
Timp3 expression in mOS-379 cells expressing scrambled or Sox2 shRNAs as indicated. All
values are normalized to actin and expressed relative to expression in cells expressing
scrambled shRNA.
(D) Wnt reporter activity in osteospheres. Relative luciferase activity in total (adherent)
cells and osteospheres from mOS-379 cells expressing TOPFLASH luciferase reporter
plasmid.
(E) Expression of Osterix and Runx2 in osteospheres. Real-time quantitative PCR
analysis of Runx2 and Osterix expression in osteospheres and adherent cells, as in (D).
(F) Expression of Sox2 in osteospheres. Real-time quantitative PCR analysis of Sox2
expression in osteospheres and adherent cells, as in (D).
Basu-Roy et al. Page 21
Oncogene. Author manuscript; available in PMC 2012 November 03.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 7. Activation of Wnt signaling decreases Sox2 expression in osteoblasts and osteosarcoma
(A) Sox2 Expression in Wnt-treated cells. Western blot of Sox2 in osteosarcoma cells
(mOS-482), immortalized osteoblasts (OB1). and primary osteoblasts transduced with empty
vector (-) or Sox2 (+) lentivirus, after treatment with control or Wnt 3A conditioned medium
for 48 hours. γ- tubulin was used as a loading control.
(B) Model for Sox2-Wnt antagonism in osteosarcoma. Undifferentiated osteosarcoma
cells with high Sox2 expression and low Wnt pathway activity are in a stem-like,
multipotent, self-renewing state.suggesting that Sox2 and Wnt pathway are mutually
antagonistic in osteosarcoma development. Sox2 depletion or activation of Wnt signaling
leads to a more differentiated, osteoblast-like state.
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Table 1
Limiting dilution analysis of osteosphere-forming frequency of Sca-1HI Sox2HI and
Sca-1LO Sox2LO cells from mOS-482
Number of cells/well Number of wells plated Number of wells with osteospheres
Sca-1HI Sox2HI Sca-1LO Sox2LO
1000 24 24 24
100 84 84 78
10 84 34 5
1 84 4 0
Sphere-forming frequency (95% CI) 1/18 (1/14-1/24) 1/50 (1/40-1/64)
P value <0.0001
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